Arthritis Rx for Skin Disorders: 40.0% of denials overturned
In 15 California IMR decisions from 2008 to 2025, reviewers overturned 6 (40.0%). In the last five years: 80.0% of 5. 11 were medical-necessity disputes, 4 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 2 | 100.0% |
| 2022 | 1 | 100.0% |
| 2024 | 1 | 100.0% |
| 2025 | 1 | 0.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 6 | 83.3% | 40.0% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 5 | 0.0% | 40.0% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 4 | 0.0% | 40.0% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Otezla. The records document that the patient’s cutaneous lichen planus is not under control despite treatment with tretinoin, clobetasol, triamcinolone, and Azelex. Per the American Academy of Dermatology (AAD), there is a lack of step therapy guidelines in place for patients with …”
“Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for (1) Xeljanz extended release 11 mg tablets and (2) Humira injector pen 40 mg/0.4 mL subcutaneous kit. Findings: The physician reviewer found that there are few therapies for the treatment of moderate-to-severe hidradenitis suppurativa (HS), Humira has been studied and approved by the U.S. Food and Drug …”
“Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Xeljanz. Findings: The physician reviewer found that some excellent promise in the treatment of severe alopecia areata. According to the Alopecia Areata Consensus of experts, there was consensus on the effectiveness of monotherapy with oral corticosteroids, cyclosporine, and Janus kinase (JAK) inhibition therapy as well as combination …”
And one the reviewer upheld
“Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Otezla, to be used in combination with Skyrizi. Neither the American College of Rheumatology/National Psoriasis Foundation nor the European Alliance of Associations for Rheumatology (EULAR) recommends the combination of Otezla and Skyrizi as being more beneficial than standard treatment options for psoriatic arthritis, including anti-interleukin (IL)-17 therapy, …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Arthritis Rx denials for Skin Disorders overturned?
In 15 California IMR decisions from 2008 to 2025, reviewers overturned 6 (40.0%). In the last five years: 80.0% of 5. 11 were medical-necessity disputes, 4 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.